trial

Carnosine and Cognitive Training in Schizophrenia

NCTId NCT02686697
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2, Phase 3 · Completed
Enrollment 60 (actual)
Sponsored by Abraham Reichenberg
Primary completion 2022-07-19
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2, Phase 3
Status
Completed
Enrollment
60 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2015-12-01
Primary completion
2022-07-19
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
L-CarnosineCognitive training

Sponsors

Abraham ReichenbergLead Sponsor
Stanley Medical Research InstituteCollaborator

Investigators

1
Avi Reichenberg, PhDPrincipal Investigator

Sites

1 total
New York, United States

Linked catalysts

1
Carnosine and Cognitive Training in Schizophrenia — primary completion2022-07-19

Facts & assertions

4 sourced
Enrollment
60
Phase
PHASE2,PHASE3
Primary Completion Date
2022-07-19
Status
COMPLETED
relationships
The graph out of here
drug
L-Carnosine
drug
Cognitive training
drug
lead_sponsor
Abraham Reichenberg
company
collaborator
Stanley Medical Research Institute
company
indication
Schizophrenia
indication
Schizophrenia
indication
Psychotic Disorders
indication
investigator
Avi Reichenberg, PhD
person